{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4ILi-48LDA","lastupdate":"2022-12-07T00:00:00.000Z","update_date":"2022-12-07T00:00:00.000Z","lastModified":"Oct 20, 2024","active":1,"confidence_score":99,"confidence_score_reason":"markets","urlname":"simplivia-healthcare","minimal_profile":null,"status":"Acquired","fullstatus":"Acquired by FIMI Opportunity Funds on May, 2019","acquired":1,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$0XbQARuGJJqlkdwfzRx5PyuDlWABnkwzAsmwBGqTA4kAbVBv3mAMxC","name":"Simplivia Healthcare","oneliner":"Closed-system Transfer Device for Safe Compounding and Administration","registrar":"515982189","website":"https://www.simplivia.com","careerspage":"","founded_month":2,"founded_year":2019,"formernames":["Monfort Medical"],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/user/tevadaptor","facebook":"","linkedin":"https://www.linkedin.com/company/29279723","instagram":""},"social":["https://www.youtube.com/user/tevadaptor","https://www.linkedin.com/company/29279723"],"flattenedsociallinks":"https://www.youtube.com/user/tevadaptor|https://www.linkedin.com/company/29279723","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"51-200","employees_exact":55,"patent":1,"raised":0,"stage":"Acquired","public_stage":"Acquired","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Simplivia™","Simplivia","SIMPLIVIA HEALTHCARE","OnGuard"],"about":"Simplivia Healthcare develops and manufactures high-quality drug-delivery solutions to ensure the safety of healthcare professionals. \r\n\r\nSimplivias Tevadaptor and Chemfort products use the companys patented Toxi-Guard system, located in the vial adaptor, to allow pressure equalization during use, preventing the escape of hazardous drug vapors into the environment during drug reconstitution and administration as well as preventing airborne contaminants and particles from entering the drug vial.\r\n\r\nTevadaptor was formerly a business unit in Teva Pharmaceutical Industries. In May 2019, Simplivia Healthcare incorporated Tevadaptor after the business unit was acquired by FIMI Opportunity Funds, an Israeli private equity firm.\r\n\r\nIn the U.S., Simplivias products are distributed exclusively by B. Braun under the brand name OnGuard. Tevadaptor and Chemfort are approved by the worlds leading regulatory bodies. The companys manufacturing facility in Kiryat Shmona, Israel, meets the most rigorous standards, with both FDA and CE approval.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"38e367d1-a4a2-44e1-bb99-2f9a9a15acb3","city":"Kiryat Shmona","type":null,"address":"איזור תעשייה צפוני, Kiryat Shmona, Israel","placeid":"ChIJt8aQlmq9HhURZdlNP4aBv_0","notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"North District","news":[{"id":"2d2ffd85-9481-46d0-86d9-215e97f98ebc","date":"Feb 10, 2022","link":"https://www.calcalist.co.il/market/article/h1tb11tzjq","source":"www.calcalist.co.il","visible":1,"analysis":{"tags":"Investment, Public Trading","company":"Simplivia","layoffs":"N/A","summary":"Simplivia, a medical equipment manufacturer, is planning to raise 300 million NIS in an IPO on the Tel Aviv Stock Exchange, valuing the company at 1.2 billion NIS. The company was acquired by FIMI, Phoenix Insurance Company, and Bank Leumi in 2019 for 170 million NIS. Simplivias products, which protect medical staff from exposure to dangerous substances, are sold in over 30 countries. The companys annual sales volume is 250 million NIS, and together with Novamed, which it acquired a controlling stake in 2021, sales reach 400 million NIS.","partners":"FIMI, Phoenix Insurance Company, Bank Leumi","customers":"N/A","investors":"FIMI, Phoenix Insurance Company, Bank Leumi","confidence":8,"key_topics":"Investment, Public Trading, Acquisition, Medical Equipment","date_of_event":"N/A","valuation_amount":"1.2 billion NIS","impact_on_company":"growth-positive","investment_amount":"300 million NIS","structured_issues":"Investment, Public Trading","acquisition_amount":"N/A","structuredIssuesShow":"#Investment, Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fj3wflTQ4qrWzdprQoF7y9heQsuJ5Pz26NTuEyCSgYn69VW9I2CP3v","news_summary":"פימי תנפיק את סימפליויה בשווי של פי 7 לעומת הרכישה מטבע  כלכליסט","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ea8b256f-b958-4ab3-84de-61893b4e3b08","date":"Jan 5, 2021","link":"https://en.globes.co.il/en/article-simplivia-healthcare-buys-diagnostics-co-novamed-1001356018","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Simplivia Healthcare Ltd.","layoffs":null,"summary":"Simplivia Healthcare Ltd., a drug delivery company, has acquired 70% of diagnostics company Novamed at a valuation of NIS 24 million. The acquisition was facilitated by Value Base M&A Israel. Simplivia develops and manufactures closed system transfer devices to protect medical professionals from exposure to hazardous drugs. Novamed is an Israeli developer and manufacturer of diagnostic platforms. The acquisition will allow Novamed to expand its global reach through Simplivias marketing channels and expertise in the medical device field.","partners":null,"customers":null,"investors":"FIMI Opportunity Funds","confidence":9,"key_topics":["Simplivia Healthcare","Novamed","acquisition","diagnostics","investment"],"date_of_event":"January 5, 2021","valuation_amount":"NIS 24 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"V7tzzPcRTkJJSkyw1oq9a1IZOCGPtUrZWenegMvR0uLaiaSLFf5fMl","news_summary":"Simplivia Healthcare buys diagnostics co Novamed","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"73359d87-19f8-417d-813d-ac652db9c8fd","date":"Oct 22, 2020","link":"https://en.globes.co.il/en/article-fimi-sells-33-of-medical-equipment-co-simplivia-1001346771","source":"en.globes.co.il","visible":1,"analysis":{"tags":"investment, acquisition","company":"Simplivia","layoffs":null,"summary":"Private equity firm FIMI Opportunity Funds has sold 33% of the shares in healthcare company Simplivia to The Phoenix Holdings Ltd. and Leumi Partners for $47 million, at a company valuation of $140 million. FIMI bought the business from Teva Pharmaceutical Industries and set up Simplivia in 2019 at an investment of $47.5 million. FIMI has made a return of $67 million on its investment and will continue to hold 65% of the company.","partners":["The Phoenix Holdings Ltd.","Leumi Partners"],"customers":null,"investors":["The Phoenix Holdings Ltd.","Leumi Partners"],"confidence":9,"key_topics":["Private equity","Healthcare company","Shares","Valuation","Investment"],"date_of_event":"October 22, 2020","valuation_amount":"$140 million","impact_on_company":"growth-positive","investment_amount":"$47 million","structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cptuVp7kpD98i538BZEWS3MW6i2EvZ6RGYiV7KFxeiSIiixlbC8Qc6","news_summary":"FIMI sells 33% of medical equipment co Simplivia","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ced71c9b-e775-4692-aea3-0c1824b23874","date":"May 1, 2019","link":"https://en.globes.co.il/en/article-fimi-completes-acquisition-of-tevas-kiryat-shmona-plant-1001284188","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"FIMI Opportunity Funds","layoffs":null,"summary":"FIMI Opportunity Funds has completed the acquisition of the Migada plant in Kiryat Shmona from Teva Pharmaceutical Industries for $47.5 million. The acquired plant, Tevadaptor, produces a closed system for protecting medical teams against exposure to hazardous materials. Ori Yehudai, former CEO of Frutarom, will join Tevadaptor as chairman. Tevadaptor currently has 200 employees and is profitable. Tevas streamlining plan aims to save $3 billion in costs and reduce debt. Tevas market cap is $16.6 billion.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["acquisition","appointment","growth potential","profitability","streamlining plan"],"date_of_event":"May 1, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":"$47.5 million","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iuPsEX3y0ww4oVSqPIIXtcS3r0NFh3BDXHSdMKyLruXqfgDGUNnOMY","news_summary":"FIMI completes acquisition of Teva's Kiryat Shmona plant","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":4,"techcommunityinvolvement":null,"mediagallery":[{"id":"ac754b79-3df3-48c9-9723-bce88d8118f1","timestamp":"2020-05-24 10:34:22.000000","resources_type":2,"resources_title":"","resources_file_name":"sFNE6O888X4","alt":"","imageurl":"https://img.youtube.com/vi/sFNE6O888X4/0.jpg","url":"http://youtu.be/sFNE6O888X4"},{"id":"bf345b5b-052a-4b7d-a8f2-7a249884e867","timestamp":"2019-08-27 07:27:11.000000","resources_type":2,"resources_title":"About Tevadaptor closed system transfer device","resources_file_name":"-mQsPT0ve8o","alt":"About Tevadaptor closed system transfer device logo","imageurl":"https://img.youtube.com/vi/-mQsPT0ve8o/0.jpg","url":"http://youtu.be/-mQsPT0ve8o"}],"tags":["oncology","medical-devices","medical-equipment","veterinary","hygiene","pharmaceuticals","doctors","medical-products","drug-delivery","laboratories","medical-technologies"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[{"id":"64XoRnDgwn37NF0MRlVjWcQXkNFYBYs7XVl6IuV4NqnO13LYzMtFPJ","link":"https://www.simplivia.com/products/chemfort-closed-administration-components-cadm/bag-adaptor-port/","name":"Chemfort™ Bag Adaptor CP","ai_analysis":{"Confidence":0.9,"created_at":"2025-07-22T19:00:15.192Z","Revenue Growth":2,"Risk Mitigation":5,"Industry Vertical":"Healthcare","ready_for_display":false,"Talent Development":4,"Agility & Innovation":3,"Customer Acquisition":3,"Operational Efficiency":4,"Short Solution Description":"The Chemfort™ Bag Adaptor CP is a component of a closed administration system designed for the safe and closed transfer of hazardous drugs from IV bags. It prevents drug exposure to healthcare professionals, reduces contamination risk, and ensures compliance with NIOSH, ASHP, and USP <800> guidelines."}},{"id":"ISVY4npDw4Xcw8eIk6s6bW5ZoGIIQsCMXOuM6kdO8KW2fzL43pWVZB","link":"https://www.bbraunusa.com/en/products/b/onguard-closed-systemtransferdevicecstd.html","name":"OnGuard® Closed System Transfer Device (CSTD)","ai_analysis":{"Confidence":0.9,"created_at":"2025-07-22T20:03:48.747Z","Revenue Growth":2,"Risk Mitigation":4,"Industry Vertical":"Healthcare","ready_for_display":false,"Talent Development":3,"Agility & Innovation":2,"Customer Acquisition":3,"Operational Efficiency":3,"Short Solution Description":"A Closed System Transfer Device (CSTD) designed to protect healthcare professionals from exposure to hazardous drugs and maintain drug sterility during preparation and administration, ensuring compliance with safety guidelines."}}],"businessmodels":["B2B"],"productstage":"Released","products":["Chemfort","Toxi-Guard","Tevadaptor"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"Undisclosed","totalrounds":0,"fundingstage":"Acquired","totalfunding":"Undisclosed","publicinvestors":0,"lastpublicfunding":null,"totalpublicrounds":0,"totalpublicfunding":0},"team":[{"name":"Oded Grinstein","email":"oded.grinstein@simplivia.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IKhzeILDA","bounced":false,"claimed":0,"founder":1,"urlname":"oded-grinstein","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgguHk2wsM","position":"CEO","last_name":"Grinstein","claimtoken":"QcZ5vfUokBVNhzem9rOY4AsX8IRsYyNs0IhCNdL3cfTA5pjs315K3X","first_name":"Oded","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/oded-grinstein-a2a0673/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-07 21:16:16.000000","initials":"OG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dima Rainer","email":"dima@simplivia.com","phone":"","gender":"Male","userid":"XgnMxjN8vkEXxpVXtmS1Uq1Jm4OWaXvYJngfSrOdWIya2zJV8vNwGI","bounced":true,"claimed":null,"founder":0,"urlname":"dima-rainer","visible":1,"memberid":"xQ65GGynv5rskBK9FKu4GTpvTmpjW8GLUieu3ja1pBUUUuvHvt2eal","position":"CCO","last_name":"Rainer","claimtoken":"QKNBVp6HGMJR0W5e6JKpyEV5IXteBBxBf25WKLrEYM10lTxbyMT4Kb","first_name":"Dima","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dima-rainer/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-12-07 21:21:26.000000","initials":"DR","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"David  Delouya","email":"david.delouya@simplivia.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4ILT4LMLDA","bounced":true,"claimed":0,"founder":1,"urlname":"david-delouya","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgwvup9AoM","position":"CFO","last_name":"Delouya","claimtoken":"ak6D8Nnpb0bBfor9aqWbiBkmOh1N7AZ3nWm3qWPW2XxEYlCZo3GGBP","first_name":"David ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/david-deluya-03709a29/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-12-07 21:16:20.000000","initials":"DD","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dana German","email":"dana.german@simplivia.com","phone":"0526146349","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4M3RvZkKDA","bounced":false,"claimed":1,"founder":0,"urlname":"dana-german","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgzYOOiQsM","position":"Marketing Communications Manager","last_name":"German","claimtoken":"31db9644ffcc8bd13519ed365bff8780e6c20047baf02808d1a3bfb1db49a379","first_name":"Dana","picturekey":null,"claimeddate":"2020-12-06","linkedinurl":"https://www.linkedin.com/in/dana-german-171264132/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2020-12-06 10:09:25.000000","initials":"DG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPW8rMQKDA","fullname":"Lena Rogovina"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPu-g88JDA","fullname":"Maor Perlov"},"biverifydate":"2020-05-24T00:00:00.000Z","crunchbaseid":"simplivia-healthcare","lastupdator":"Matan Eblagon","lastupdator_email":"matane@sncentral.org","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2019-08-27T00:00:00.000Z","biverification":"Maor Perlov","sectorverification":"Lena Rogovina","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCz8v6NCgw","date":"Jan 2021","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-simplivia-healthcare-buys-diagnostics-co-novamed-1001356018","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Novamed","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6M0bYIDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/novamed","acquiredcompany_mna_logokey":"$eWdJ5Us8ZF338sJu3Dd3gY0YW65uWKi0hP7GTbFbJzvwbMLT8u6H65","acquiredcompany_mna_urlname":"/company_page/novamed","acquiredcompany_mna_homepage":"https://www.novamed.co.il","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$eWdJ5Us8ZF338sJu3Dd3gY0YW65uWKi0hP7GTbFbJzvwbMLT8u6H65","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODit_SOCww","date":"May 2019","amount":"$47.5M","source":"https://en.globes.co.il/en/article-fimi-completes-acquisition-of-tevas-kiryat-shmona-plant-1001284188","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"FIMI Opportunity Funds","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNHKoJgJDA","acquiredcompany_mna_type":"Investor","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/investor_page/fimi-opportunity-funds","acquiredcompany_mna_logokey":"$T0ANpJv6HDtgD1g6FLLyS6M8R4mLHHPU5KlTHsEETCYbYGWrauwIGq","acquiredcompany_mna_urlname":"/investor_page/fimi-opportunity-funds","acquiredcompany_mna_homepage":"http://www.fimi.co.il/","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$T0ANpJv6HDtgD1g6FLLyS6M8R4mLHHPU5KlTHsEETCYbYGWrauwIGq","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":47500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"2/2019","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Simplivia Healthcare","logourl":"https://storage.googleapis.com/clean-finder-353810/$0XbQARuGJJqlkdwfzRx5PyuDlWABnkwzAsmwBGqTA4kAbVBv3mAMxC","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$0XbQARuGJJqlkdwfzRx5PyuDlWABnkwzAsmwBGqTA4kAbVBv3mAMxC","seoabout":"Simplivia Healthcare develops and manufactures high-quality drug-delivery solutions to ensure the safety of healthcare professionals. \r\n\r\nSimplivias Tevada...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drug Delivery","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drug Delivery"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drug Delivery"],"coreTechnology":["Materials & Substances"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODit_SOCww","date":"May 2019","amount":"$47.5M","source":"https://en.globes.co.il/en/article-fimi-completes-acquisition-of-tevas-kiryat-shmona-plant-1001284188","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"FIMI Opportunity Funds","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNHKoJgJDA","acquiredcompany_mna_type":"Investor","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/investor_page/fimi-opportunity-funds","acquiredcompany_mna_logokey":"$T0ANpJv6HDtgD1g6FLLyS6M8R4mLHHPU5KlTHsEETCYbYGWrauwIGq","acquiredcompany_mna_urlname":"/investor_page/fimi-opportunity-funds","acquiredcompany_mna_homepage":"http://www.fimi.co.il/","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$T0ANpJv6HDtgD1g6FLLyS6M8R4mLHHPU5KlTHsEETCYbYGWrauwIGq","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":47500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCz8v6NCgw","date":"Jan 2021","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-simplivia-healthcare-buys-diagnostics-co-novamed-1001356018","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Novamed","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6M0bYIDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/novamed","acquiredcompany_mna_logokey":"$eWdJ5Us8ZF338sJu3Dd3gY0YW65uWKi0hP7GTbFbJzvwbMLT8u6H65","acquiredcompany_mna_urlname":"/company_page/novamed","acquiredcompany_mna_homepage":"https://www.novamed.co.il","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$eWdJ5Us8ZF338sJu3Dd3gY0YW65uWKi0hP7GTbFbJzvwbMLT8u6H65","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}